OHOrly Haskin

Orly Haskin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Orly Haskin has a total of 76 co-authors. Here are the top co-authors by number of shared publications:

  • Miriam Davidovits

    Institute of Nephrology, Schneider Children's Medical Center of Israel, Petach Tikva, Israel

    5 shared publications
  • Daniel Landau

    Nephrology Department, Schneider Children’s Medical Center of Israel, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel

    4 shared publications
  • Hadas Alfandary

    4 shared publications
  • Yael Borovitz

    3 shared publications
  • Yafa Falush

    Institute of Nephrology, Schneider Children's Medical Center of Israel, Petach Tikva, Israel

    3 shared publications
  • Amit Dagan

    Institute of Nephrology, Schneider Children’s Medical Center of Israel, Petah Tikva, Israel

    2 shared publications

Latest Publications

  • Open Access

    Thrombotic Microangiopathy in Childhood Steroid-Resistant Nephrotic Syndrome: Case Series

    by Dor Fisher, Orly Haskin, Daniel Landau, Yael Borovitz, Choni Rinat, Hadas Alfandary

    Introduction: Thrombotic microangiopathy (TMA) with associated nephrotic syndrome is a unique and rare condition that is infrequently described in pediatrics. Case Presentations: Four children with steroid-resistant nephrotic syndrome (SRNS), immune-mediated and of monogenic origin, presented with TMA during late stages of chronic kidney disease. All patients tested negative for Shiga toxin and had normal A Disintegrin-like and Metalloprotease with Thrombospondin type 1 repeats 13 (ADAMTS13) activity. Genetic and functional studies of complement dysregulation were negative. Three of the 4 patients treated with Eculizumab showed good hematologic response but no kidney function recovery. None of the three children who underwent kidney transplantation had recurrent TMA. Conclusions: TMA may develop in patients with SRNS, manifesting as an unexplained worsening of kidney function, new-onset hypertension, hemolytic anemia, and thrombocytopenia. Eculizumab was effective in improving hemolytic markers without kidney function recovery. TMA did not recur after kidney transplantation in this entity.

  • Open Access

    Response to the letter of Deng et al

    by Orly Haskin, Nadin Kannan, Daniel Landau

  • Open Access

    Patterns of damage observed on dimercaptosuccinic acid kidney scans and future risk of urinary tract infections or reduced kidney function

    by Nadin Kanaan, Shiri Cooper, Daniel Landau, Zvi Bar Sever, Orly Haskin

    Background: 99m Tc-Dimercaptosuccinic acid (DMSA) scan is highly accurate for assessing functional imaging of the kidney parenchyma. Kidney damage observed on DMSA scan is associated with future development of chronic kidney disease. This study aims to differentiate between different patterns of damage observed on DMSA scan and determine their predictive clinical value. Methods: We reviewed first-in-life DMSA scans performed ≥ 4 months post febrile urinary tract infection (UTI) or for suspected congenital kidney abnormalities, in a single referral center, from November 2007 to February 2011. DMSA uptake patterns were classified as normal; peripheral focal defects; diffuse inhomogeneity in tracer distribution within kidney parenchyma; and the combination of both patterns. Subsequent UTIs and estimated glomerular filtration rate (eGFR) were recorded at last follow-up. Results: One hundred five patients met inclusion criteria, and 57 (54%) were females. Median (IQR) age at scan was 2 (1.3, 5.1) years. Fourteen patients (13.3%) had focal defects, 29 (27.6%) had diffuse inhomogeneity and 9 (8.6%) had diffuse inhomogeneity with focal defects. After a mean follow-up period of 9.6 ± 3.3 years (available for 99 children), 29 (29%) patients experienced recurrent UTIs [median (IQR) episodes: 2 (1, 5)]. UTI tendency differed between groups (focal defects: 71.4%; diffuse inhomogeneity with focal defect: 44.4%; diffuse inhomogeneity only: 22.2%; normal scan: 18.3% p < 0.001). On multivariate analysis only the presence of focal defects predicted recurrent UTIs [OR (95%CI): 3.89 (1.2, 12.6), p = 0.024]. The percentage of patients with an eGFR < 75 ml/min/1.73 m 2 , was highest in patients with diffuse inhomogeneity with focal defects compared to patients with normal scans, focal defects only or diffuse inhomogeneity only (22% vs. 2%, 0% and 3.7% respectively, p = 0.032). Conclusions: Focal defects on DMSA scan, likely representing post pyelonephritis scars, are a strong predictor of recurrent UTIs. Patients with diffuse inhomogeneity with focal defects on scan have the highest risk of reduced eGFR during follow-up. Graphical


  • Incremental hemodialysis in pediatric patients

    by Gurevich Evgenia, Falush Yafa, Alfandari Hadas, Levi Shelly, Dagan Amit, Daniel Landau, Haskin Orly

    Background Incremental hemodialysis follows the concept of adjusting dialysis dose according to residual kidney function. Data on incremental hemodialysis in pediatric patients is lacking. Methods We conducted a retrospective analysis of children initiating hemodialysis between January 2015 and July 2020 in a single tertiary center, comparing the characteristics and outcomes of those who commenced with incremental hemodialysis vs with conventional thrice-weekly regimen. Results Data on forty patients, 15 (37.5%) on incremental hemodialysis and 25 (63%) on thrice-weekly hemodialysis were analyzed. No differences in age, estimated glomerular filtration rate and metabolic parameters were noted between groups at baseline, but there were more males (73 vs 40%, p = 0.04), more patients with congenital anomalies of kidney and urinary tract (60 vs 20%, p = 0.01), higher urine output (2.5 ± 1 vs 1 ± 0.8 ml/kg/h, p < 0.001), lower use of antihypertensive medications (20 vs 72%, p = 0.002) and lower prevalence of left ventricular hypertrophy (6.7 vs 32%, p = 0.003) in the incremental hemodialysis group vs thrice-weekly hemodialysis. During follow up, 5 (33%) incremental hemodialysis patients were transplanted, 1 (7%) remained on incremental hemodialysis at 24 months, and 9 (60%) transitioned to thrice-weekly hemodialysis at a median (IQR) time of 8.7 (4.2, 11.8) months. At last follow up, fewer patients who initiated incremental hemodialysis had left ventricular hypertrophy (0 vs 32%, p = 0.016) and urine output < 100 ml/24 h (20 vs 60%, p = 0.02) compared to thrice-weekly hemodialysis, with no significant differences in metabolic or growth parameters. Conclusion Incremental hemodialysis is a viable option for initiating dialysis in selected pediatric patients, that may help improve patients’ quality of life and reduce dialysis burden without compromising clinical outcome. Graphical abstract


  • Serological Response to the BNT162b2 COVID-19 mRNA Vaccine in Adolescent and Young Adult Kidney Transplant Recipients

    by Orly Haskin, Liat Ashkenazi-Hoffnung, Noa Ziv, Yael Borovitz, Amit Dagan, Shelly Levi, Gili Koren, Gilad Hamdani, Daniella Levi-Erez, Daniel Landau, et al.

    Background.: Initial reports in adult kidney transplant recipients (KTR) indicate low immunogenicity after 2 doses of the BNT162b2 COVID-19 mRNA vaccine. We describe the immunogenicity of this vaccine compared to the serologic response in naturally infected COVID-19 positive adolescent and young adult KTR. Methods.: For this prospective observational study, the study group included 38 KTR who received 2 doses of the tested vaccine, and the control group included 14 KTR who had a previous polymerase chain reaction–confirmed COVID-19 infection. Results.: The mean age was 18 ± 3 y. Positive serologic responses were observed in 63% and 100% of the study and control groups, respectively (P = 0.01). Antibody titers were almost 30-fold higher in the control than the study group (median [interquartile range (IQR)]: 2782 [1908–11 000] versus 100.3 [4.7–1744] AU/mL, P < 0.001), despite the longer time from the COVID-19 infection to serologic testing compared to time from vaccination (median [IQR]: 157.5 [60–216] versus 37 [20.5–53] d, P = 0.011). Among vaccinated patients, higher proportions of those seronegative than seropositive were previously treated with rituximab (50% versus 8%, P = 0.01). Time from the second vaccine dose to serologic testing was longer in seropositive than seronegative patients (median [IQR]: 24.5 [15–40] versus 46 [27–56] d, P = 0.05). No patient developed symptomatic COVID-19 disease postvaccination. Conclusions.: The BNT162b2 COVID-19 mRNA vaccine yielded higher positive antibody response in adolescent and young adult KTR than previously reported for adult KTR. Antibody titers after vaccination were significantly lower than following COVID-19 infection. Longer time may be required to mount appropriate humoral immunity to vaccination in KTR.


  • Open Access

    Use of Point-of-Care Ultrasound for Evaluation of Extravascular and Intravascular Fluid Status in Pediatric Patients Maintained on Chronic Hemodialysis

    by Orly Haskin, Yafa Falush, Miriam Davidovits, Hadas Alfandary, Shelly Levi, Ron Berant

    Aims: Traditional methods that use clinical parameters to determine dry weight in hemodialysis patients are inaccurate. This study aimed to compare clinical assessment of fluid status to sonographic parameters of fluid status in pediatric patients undergoing chronic hemodialysis. Methods: In a prospective observational study, pediatric patients maintained on chronic hemodialysis (ages 2.3–20 years) were evaluated clinically and sonographically before and after dialysis at 6 consecutive sessions. Sonographic parameters examined were number of lung B-lines as a measure of extravascular volume and inferior vena cava (IVC)/aorta ratio as a measure of intravascular volume. Clinical assessment of fluid status was compared to sonographic assessment. Results: Twelve patients were evaluated during 72 dialysis sessions. Sonographic parameters were significantly lower post-dialysis than pre-dialysis (B-lines number 4.5 ± 5 vs. 7.69 ± 7.46, p < 0.0001; IVC/aorta ratio 0.9 ± 0.2 vs. 1.1 ± 0.2, p < 0.0001, respectively). Ultrafiltration volume correlated with change in B-lines number during dialysis (r = 0.39, p < 0.01). Percent of blood volume drop correlated with post-dialysis IVC/aorta ratio (r = 0.48, p < 0.001). A higher percent of symptomatic episodes occurred with post-dialysis IVC/aorta ratio p = 0.036). Four patients were hypertensive, a clinical parameter implying fluid overload, in only one sonographic evaluation indicated fluid overload. Eight patients were clinically determined to be euvolemic, in three of them sonographic evaluation discovered covert fluids. Conclusion: Bedside ultrasound is a single modality that can be used to assess both extravascular and intravascular fluid status. It may contribute to clinical decisions differentiating fluid-related versus fluid-unrelated hypertension and identifying patients with covert fluids.


  • Peri-transplant aminophylline in pediatric kidney transplant recipients of donation after brain death: a double-blinded placebo-controlled randomized clinical trial

    by Orly Haskin, Weiwen Shih, Cynthia J Wong, David M Axelrod, Paul C Grimm

    Background During kidney transplantation, the transplanted kidney undergoes ischemia reperfusion injury, with adenosine being a major mediator. This study aimed to assess whether aminophylline, an adenosine receptor antagonist, improves early graft function and reduces incidence of delayed graft function (DGF) and slow graft function (SGF). Methods Single center, double-blinded, placebo-controlled randomized clinical trial. Pediatric patients admitted for renal transplantation from donation after brain death donors were randomized into a treatment arm receiving aminophylline and a placebo arm receiving normal saline infusions. Primary outcome was estimated glomerular filtration rate (eGFR) at 5 days post-transplant. Secondary outcomes were rates of DGF/SGF and urinary neutrophil gelatinase–associated lipocalin (NGAL) levels. Results Twenty-three patients were randomized to aminophylline and 27 to placebo. There was no difference in day 5 eGFR, rate of DGF/SGF, or urine NGAL/Creatinine level between aminophylline vs. placebo arm (eGFR 67.39 ± 38.9 ml/min/1.73m2 vs. 80.48 ± 52.1 ml/min/1.73m2p = 0.32; DGF/SGF 5/23 (21.7%) vs. 3/27 (11.1%) p = 0.31; urine NGAL/creatinine 300.5 ng/mg IQR 105.5–1464.5 ng/mg vs. 425.4 ng/mg IQR 140.3–1126.2 ng/mg, p = 0.95; respectively). At 12 months, there was 100% patient survival and 98% graft survival. eGFR at 12 months was similar between the two arms. Conclusions There was no benefit in peri-transplant aminophylline administration. Our results are limited by small sample size, since sample calculations were based on primary outcome of day 5 eGFR and low rate of DGF/SGF, which may have precluded us from demonstrating efficacy. Further clinical studies are necessary to determine any benefit of aminophylline in kidney transplant recipients, particularly from high-risk donors.

  • Lower prednisone dosing for steroid-sensitive nephrotic syndrome relapse: a prospective randomized pilot study

    by Yael Borovitz, Hadas Alfandary, Orly Haskin, Shely Levi, Shulamit Kaz, Miriam Davidovits, Amit Dagan

    Relapses of steroid-sensitive nephrotic syndrome are traditionally treated with prednisone 2 mg/kg/day or 60 mg/m2/day. Retrospective data support the use of lower doses. We designed a prospective randomized pilot study to investigate the efficacy of different doses in achieving remission of steroid sensitive nephrotic syndrome relapse. The cohort included 30 children with relapsed steroid sensitive nephrotic syndrome, mean age 6.3 ± 3 years and mean disease duration 2.2 ± 1.8 years. The children were randomized to receive 2, 1.5, or 1 mg/kg/day prednisone. The corresponding times to response, defined as the first of 3 consecutive days without proteinuria, were 7.2 ± 1.4, 10.2 ± 5.1, and 9 ± 3.3 days; the difference between the 1.5 and 2 mg/kg/day groups was statistically significant. One patient each in the 1 mg/kg/day and the 1.5 mg/kg/day groups failed to respond and were switched to 2 mg/kg/day, leading to a response after 3 and 10 days, respectively. Mean cumulative prednisone doses in the 3 groups were 45.5 ± 3.4, 42.7 ± 25.9, and 24.9 ± 7.4 mg/kg, respectively (P < 0.05).


  • Is eculizumab indicated in patients with atypical hemolytic uremic syndrome already on prolonged dialysis? A case report and review of the literature

    by Orly Haskin, Yafa Falush, Miriam Davidovits

    Eculizumab has caused a revolution in the treatment and prognosis of atypical hemolytic uremic syndrome. Early initiation of treatment is recommended to increase chances of renal recovery.